TY - JOUR
T1 - Chronic myeloid leukemia
T2 - A prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: A study of the GIMEMACMLWP
AU - Testoni, Nicoletta
AU - Marzocchi, Giulia
AU - Luatti, Simona
AU - Amabile, Marilina
AU - Baldazzi, Carmen
AU - Stacchini, Monica
AU - Nanni, Mauro
AU - Rege-Cambrin, Giovanna
AU - Giugliano, Emilia
AU - Giussani, Ursula
AU - Abruzzese, Elisabetta
AU - Kerim, Simonetta
AU - Grimoldi, Maria Grazia
AU - Gozzetti, Alessandro
AU - Crescenzi, Barbara
AU - Carcassi, Carlo
AU - Bernasconi, Paolo
AU - Cuneo, Antonio
AU - Albano, Francesco
AU - Fugazza, Giuseppina
AU - Zaccaria, Alfonso
AU - Martinelli, Giovanni
AU - Pane, Fabrizio
AU - Rosti, Gianantonio
AU - Baccarani, Michele
PY - 2009/12/3
Y1 - 2009/12/3
N2 - In chronic myeloid leukemia, different methods are available to monitor the response to therapy: chromosome banding analysis (CBA), interphase fluorescence in situ hybridization (I-FISH), and real-time quantitative polymerase chain reaction (RT-Q-PCR). The GIMEMA CML WP (Gruppo Italiano Malattie Ematologiche Adulto Chronic Myeloid Leukemia Working Party) has performed a prospective study to compare CBA and I-FISH for the definition of complete cytogenetic response (CCgR). Samples (n = 664) were evaluated simultaneously by CBA and I-FISH. Of 537 cases in CCgR, the number of positive nuclei by I-FISH was less than 1% in 444 cases (82.7%). Of 451 cases with less than 1% positive nuclei by I-FISH, 444 (98.4%) were classified as CCgR by CBA. The major molecular response rate was significantly greater in cases with I-FISH less than 1% than in those with I-FISH 1% to 5% (66.8% vs 51.6%, P <.001) and in cases with CCgR and I-FISH less than 1% than in cases with CCgR and I-FISH 1% to 5% (66.1% vs 49.4%, P = .004). I-FISH is more sensitive than CBA and can be used to monitor CCgR. With appropriate probes, the cutoff value of I-FISH may be established at 1%. These trials are registered at http://www.clinicaltrials.gov as NCT00514488 and NCT00510926.
AB - In chronic myeloid leukemia, different methods are available to monitor the response to therapy: chromosome banding analysis (CBA), interphase fluorescence in situ hybridization (I-FISH), and real-time quantitative polymerase chain reaction (RT-Q-PCR). The GIMEMA CML WP (Gruppo Italiano Malattie Ematologiche Adulto Chronic Myeloid Leukemia Working Party) has performed a prospective study to compare CBA and I-FISH for the definition of complete cytogenetic response (CCgR). Samples (n = 664) were evaluated simultaneously by CBA and I-FISH. Of 537 cases in CCgR, the number of positive nuclei by I-FISH was less than 1% in 444 cases (82.7%). Of 451 cases with less than 1% positive nuclei by I-FISH, 444 (98.4%) were classified as CCgR by CBA. The major molecular response rate was significantly greater in cases with I-FISH less than 1% than in those with I-FISH 1% to 5% (66.8% vs 51.6%, P <.001) and in cases with CCgR and I-FISH less than 1% than in cases with CCgR and I-FISH 1% to 5% (66.1% vs 49.4%, P = .004). I-FISH is more sensitive than CBA and can be used to monitor CCgR. With appropriate probes, the cutoff value of I-FISH may be established at 1%. These trials are registered at http://www.clinicaltrials.gov as NCT00514488 and NCT00510926.
UR - http://www.scopus.com/inward/record.url?scp=73949153481&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73949153481&partnerID=8YFLogxK
U2 - 10.1182/blood-2009-07-229864
DO - 10.1182/blood-2009-07-229864
M3 - Article
C2 - 19797518
AN - SCOPUS:73949153481
VL - 114
SP - 4939
EP - 4943
JO - Blood
JF - Blood
SN - 0006-4971
IS - 24
ER -